Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation Personalized Medicine for Long QT Syndrome

Zhu, Wandi; Mazzanti, Andrea; Voelker, Taylor L.; Hou, Panpan; Moreno, Jonathan D.; Angsutararux, Paweorn; Naegle, Kristen M.; Priori, Silvia G.; Silva, Jonathan R.

Angol nyelvű Tudományos Szakcikk (Folyóiratcikk)
Megjelent: CIRCULATION RESEARCH 0009-7330 1524-4571 124 (4) pp. 539-552 2019
  • SJR Scopus - Cardiology and Cardiovascular Medicine: D1
    Rationale: Mutations in the SCN5A gene, encoding the alpha subunit of the Nav1.5 channel, cause a life-threatening form of cardiac arrhythmia, long QT syndrome type 3 (LQT3). Mexiletine, which is structurally related to the Na+ channel-blocking anesthetic lidocaine, is used to treat LQT3 patients. However, the patient response is variable, depending on the genetic mutation in SCN5A.
    Hivatkozás stílusok: IEEEACMAPAChicagoHarvardCSLMásolásNyomtatás
    2021-01-26 22:46